|
| 37414703 | Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data. | Eur Urol | 2024 |
| 37714762 | Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. | Eur Urol Oncol | 2024 |
| 37523331 | A pilot study of an organised population-based testing programme for prostate cancer. | BJU Int | 2024 |
| 37743194 | European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. | Eur Urol | 2024 |
| 38042646 | Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. | Eur Urol | 2024 |
| 36008540 | Risk of progression following a negative biopsy in prostate cancer active surveillance. | Prostate Cancer Prostatic Dis | 2023 |
| 37627095 | Intake of the Total, Classes, and Subclasses of (Poly)Phenols and Risk of Prostate Cancer: A Prospective Analysis of the EPIC Study. | Cancers (Basel) | 2023 |
| 37708629 | Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. | Eur J Cancer | 2023 |
| 37845121 | Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. | Eur Urol Oncol | 2023 |
| 38046899 | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program. | Int J Surg Protoc | 2023 |
| 37822514 | Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial. | Eur Urol Open Sci | 2023 |
| 37179239 | Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2023 |
| 37105783 | Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer. | Eur Urol Focus | 2023 |
| 37170656 | Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up. | Scand J Urol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36858151 | Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. | Ann Oncol | 2023 |
| 36650356 | Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index. | Eur J Nucl Med Mol Imaging | 2023 |
| 36474058 | Publisher Correction: Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI. | Eur Radiol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36890837 | Correlation between ADC, ADC ratio, and Gleason Grade group in prostate cancer patients undergoing radical prostatectomy: Retrospective multicenter study with different MRI scanners. | Front Oncol | 2023 |
| 36148781 | Protein and amino acid intakes in relation to prostate cancer risk and mortality-A prospective study in the European Prospective Investigation into Cancer and Nutrition. | Cancer Med | 2023 |
| 36371606 | Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI. | Eur Radiol | 2023 |
| 32279170 | Risk of hernia formation after radical prostatectomy: a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial. | Hernia | 2022 |
| 35846415 | Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. | Nucl Med Mol Imaging | 2022 |
| 35546102 | Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study. | Scand J Urol | 2022 |
| 35475912 | Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. | Eur J Nucl Med Mol Imaging | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35379637 | Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. | BMJ Open | 2022 |
| 35697871 | EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([<sup>177</sup>Lu]Lu-PSMA). | Eur J Nucl Med Mol Imaging | 2022 |
| 35697600 | EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy. | Eur Urol Oncol | 2022 |
| 35365360 | Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer. | Eur Urol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35811285 | Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme. | Eur Urol Focus | 2022 |
| 35866190 | Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [<sup>18</sup> F]-fluorocholine PET-CT using histopathology as a reference. | Clin Physiol Funct Imaging | 2022 |
| 36332173 | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. | JCO Glob Oncol | 2022 |
| 36353661 | Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. | Eur Urol Open Sci | 2022 |
| 35917644 | The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. | Transl Oncol | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35943665 | Assessing the accuracy of [<sup>18</sup>F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. | EJNMMI Res | 2022 |
| 33583762 | Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. | Eur Urol Focus | 2022 |
| 35132753 | Lymph swelling after radical prostatectomy and pelvic lymph node dissection. | BJU Int | 2022 |
| 34980495 | A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. | Eur Urol | 2022 |
| 35279418 | Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 35275321 | Correction: Risk of hernia formation after radical prostatectomy: a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial. | Hernia | 2022 |
| 35174613 | Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden. | BJU Int | 2022 |
| 35135748 | Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. | Clin Genitourin Cancer | 2022 |
| 35259550 | Nuclear expression of pSTAT3<sup>Tyr705</sup> and pSTAT3<sup>Ser727</sup> in the stromal compartment of localized hormone-naïve prostate cancer. | Pathol Res Pract | 2022 |
| 34463809 | Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [<sup>18</sup>F]DCFPyL (PSMA) imaging for standardized reporting. | Eur J Nucl Med Mol Imaging | 2022 |
| 31345783 | Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. | Eur Urol Focus | 2021 |
| 33743059 | Urinary continence recovery and oncological outcomes after surgery for prostate cancer analysed by risk category: results from the LAParoscopic prostatectomy robot and open trial. | World J Urol | 2021 |